Clifton E Barry Iii

List of Publications by Year
in descending order

308 papers	43,550 citations	1994 101 h-index	2509 196 g-index
325 all docs	325 docs citations	325 times ranked	26055 citing authors

#	Article	IF	Citations
1	A Rabbit Model to Study Antibiotic Penetration at the Site of Infection for Nontuberculous Mycobacterial Lung Disease: Macrolide Case Study. Antimicrobial Agents and Chemotherapy, 2022, 66, aac0221221.	3.2	13
2	DNA-Dependent Binding of Nargenicin to DnaE1 Inhibits Replication in Mycobacterium tuberculosis. ACS Infectious Diseases, 2022, 8, 612-625.	3.8	11
3	Identification of Î²-Lactams Active against Mycobacterium tuberculosis by a Consortium of Pharmaceutical Companies and Academic Institutions. ACS Infectious Diseases, 2022, 8, 557-573.	3.8	13
4	Treatments of Multidrug-Resistant Tuberculosis: Light at the End of the Tunnel. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1142-1144.	5.6	10
5	Phylogenomic analysis of the diversity of graspetides and proteins involved in their biosynthesis. Biology Direct, 2022, 17, 7.	4.6	9
6	MAIT cell-directed therapy of Mycobacterium tuberculosis infection. Mucosal Immunology, 2021, 14, 199-208.	6.0	57
7	Structureâ€“Activity Relationships of Pyrazolo[1,5-a]pyrimidin-7(4H)-ones as Antitubercular Agents. ACS Infectious Diseases, 2021, 7, 479-492.	3.8	9
8	Antitubercular 2-Pyrazolylpyrimidinones: Structureâ€“Activity Relationship and Mode-of-Action Studies. Journal of Medicinal Chemistry, 2021, 64, 719-740.	6.4	9
9	Fourteen-day PET/CT imaging to monitor drug combination activity in treated individuals with tuberculosis. Science Translational Medicine, 2021, 13, .	12.4	25
10	Tuberculosis Drug Discovery: A Decade of Hit Assessment for Defined Targets. Frontiers in Cellular and Infection Microbiology, 2021, 11, 611304.	3.9	38
11	Targeting Mycobacterium tuberculosis CoaBC through Chemical Inhibition of 4â€²-Phosphopantothenoyl-<scp>l</scp>-cysteine Synthetase (CoaB) Activity. ACS Infectious Diseases, 2021, 7, 1666-1679.	3.8	3
12	Structural Basis for a Dual Function ATP Grasp Ligase That Installs Single and Bicyclic Ï‰-Ester Macrocycles in a New Multicore RiPP Natural Product. Journal of the American Chemical Society, 2021, 143, 8056-8068.	13.7	20
13	Activating Mucosal-Associated Invariant T Cells Induces a Broad Antitumor Response. Cancer Immunology Research, 2021, 9, 1024-1034.	3.4	29
14	Functional inactivation of pulmonary MAIT cells following 5-OP-RU treatment of non-human primates. Mucosal Immunology, 2021, 14, 1055-1066.	6.0	23
15	The Tuberculosis Drug Accelerator at year 10: what have we learned?. Nature Medicine, 2021, 27, 1333-1337.	30.7	32
16	Resistance of Mycobacterium tuberculosis to indole 4-carboxamides occurs through alterations in drug metabolism and tryptophan biosynthesis. Cell Chemical Biology, 2021, 28, 1180-1191.e20.	5.2	5
17	1,3-Diarylpyrazolyl-acylsulfonamides as Potent Anti-tuberculosis Agents Targeting Cell Wall Biosynthesis in Mycobacterium tuberculosis. Journal of Medicinal Chemistry, 2021, 64, 12790-12807.	6.4	13
18	Eosinophils are part of the granulocyte response in tuberculosis and promote host resistance in mice. Journal of Experimental Medicine, 2021, 218, .	8.5	38

#	Article	IF	Citations
19	Lesion Penetration and Activity Limit the Utility of Second-Line Injectable Agents in Pulmonary Tuberculosis. Antimicrobial Agents and Chemotherapy, 2021, 65, e0050621.	3.2	12
20	Radiological and functional evidence of the bronchial spread of tuberculosis: an observational analysis. Lancet Microbe, The, 2021, 2, e518-e526.	7.3	16
21	Inhibiting Mycobacterium tuberculosis CoaBC by targeting an allosteric site. Nature Communications, 2021, 12, 143.	12.8	8
22	Signature required: The transcriptional response to tuberculosis. Journal of Experimental Medicine, 2021, 218, .	8.5	3
23	Setting Our Sights on Infectious Diseases. ACS Infectious Diseases, 2020, 6, 3-13.	3.8	17
24	Development and Optimization of Chromosomally-Integrated Fluorescent Mycobacterium tuberculosis Reporter Constructs. Frontiers in Microbiology, 2020, 11, 591866.	3.5	9
25	PE/PPE proteins mediate nutrient transport across the outer membrane of Mycobacterium tuberculosis. Science, 2020, 367, 1147-1151.	12.6	110
26	Current and future treatments for tuberculosis. BMJ, The, 2020, 368, m216.	6.0	43
27	Quantitative 18F-FDG PET-CT scan characteristics correlate with tuberculosis treatment response. EJNMMI Research, 2020, 10, 8.	2.5	27
28	Inhibition of CorA-Dependent Magnesium Homeostasis Is Cidal in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	9
29	C4-Phenylthio Î²-lactams: Effect of the chirality of the Î²-lactam ring on antimicrobial activity. Bioorganic and Medicinal Chemistry, 2019, 27, 115050.	3.0	9
30	Plasticity of the Mycobacterium tuberculosis respiratory chain and its impact on tuberculosis drug development. Nature Communications, 2019, 10, 4970.	12.8	82
31	Mode-of-action profiling reveals glutamine synthetase as a collateral metabolic vulnerability of M. tuberculosis to bedaquiline. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 19646-19651.	7.1	38
32	The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis. Lancet Respiratory Medicine,the, 2019, 7, 820-826.	10.7	92
33	Targeting of Fumarate Hydratase from Mycobacterium tuberculosis Using Allosteric Inhibitors with a Dimeric-Binding Mode. Journal of Medicinal Chemistry, 2019, 62, 10586-10604.	6.4	9
34	Changes in inflammatory protein and lipid mediator profiles persist after antitubercular treatment of pulmonary and extrapulmonary tuberculosis: A prospective cohort study. Cytokine, 2019, 123, 154759.	3.2	55
35	Molecular degree of perturbation of plasma inflammatory markers associated with tuberculosis reveals distinct disease profiles between Indian and Chinese populations. Scientific Reports, 2019, 9, 8002.	3.3	33
36	Linezolid resistance in patients with drug-resistant TB and treatment failure in South Africa. Journal of Antimicrobial Chemotherapy, 2019, 74, 2377-2384.	3.0	32

#	Article	IF	Citations
37	Tuberculosis drugsâ€™ distribution and emergence of resistance in patientâ€™s lung lesions: A mechanistic model and tool for regimen and dose optimization. PLoS Medicine, 2019, 16, e1002773.	8.4	139
38	2-Mercapto-Quinazolinones as Inhibitors of Type II NADH Dehydrogenase and Mycobacterium tuberculosis: Structureâ€“Activity Relationships, Mechanism of Action and Absorption, Distribution, Metabolism, and Excretion Characterization. ACS Infectious Diseases, 2018, 4, 954-969.	3.8	49
39	Complement pathway gene activation and rising circulating immune complexes characterize early disease in HIV-associated tuberculosis. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E964-E973.	7.1	96
40	Role of Chemical Biology in Tuberculosis Drug Discovery and Diagnosis. ACS Infectious Diseases, 2018, 4, 458-466.	3.8	13
41	Transmission ofMycobacterium tuberculosisFrom Patients Who Are Nucleic Acid Amplification Test Negative. Clinical Infectious Diseases, 2018, 67, 1653-1659.	5.8	11
42	Defective positioning in granulomas but not lung-homing limits CD4 T-cell interactions with Mycobacterium tuberculosis-infected macrophages in rhesus macaques. Mucosal Immunology, 2018, 11, 462-473.	6.0	99
43	A semi-automatic technique to quantify complex tuberculous lung lesions on 18F-fluorodeoxyglucose positron emission tomography/computerised tomography images. EJNMMI Research, 2018, 8, 55.	2.5	16
44	Discovery and Structureâ€“Activity-Relationship Study of N-Alkyl-5-hydroxypyrimidinone Carboxamides as Novel Antitubercular Agents Targeting Decaprenylphosphoryl-Î²-<scp>d</scp>-ribose 2â€²-Oxidase. Journal of Medicinal Chemistry, 2018, 61, 9952-9965.	6.4	29
45	Structures of DPAGT1 Explain Glycosylation Disease Mechanisms and Advance TB Antibiotic Design. Cell, 2018, 175, 1045-1058.e16.	28.9	67
46	Storage lipid studies in tuberculosis reveal that foam cell biogenesis is disease-specific. PLoS Pathogens, 2018, 14, e1007223.	4.7	75
47	Construction of Fluorescent Analogs to Follow the Uptake and Distribution of Cobalamin (Vitamin) Tj ETQq1 1 0.784314 rgBT /Overlock	5.2	30
48	Long-acting formulations for the treatment of latent tuberculous infection: opportunities and challenges. International Journal of Tuberculosis and Lung Disease, 2018, 22, 125-132.	1.2	40
49	The present state of the tuberculosis drug development pipeline. Current Opinion in Pharmacology, 2018, 42, 81-94.	3.5	70
50	Oxazolidinones are essential in resistance-proof drug combinations in M. tuberculosis selected under in vitro conditions. International Journal of Infectious Diseases, 2018, 73, 129.	3.3	0
51	Extreme Drug Tolerance of Mycobacterium tuberculosis in Caseum. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	159
52	Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistance. Nature Genetics, 2017, 49, 395-402.	21.4	258
53	The within-host population dynamics of Mycobacterium tuberculosis vary with treatment efficacy. Genome Biology, 2017, 18, 71.	8.8	95
54	Fragment-Sized EthR Inhibitors Exhibit Exceptionally Strong Ethionamide Boosting Effect in Whole-Cell Mycobacterium tuberculosis Assays. ACS Chemical Biology, 2017, 12, 1390-1396.	3.4	24

#	Article	IF	Citations
55	Evaluation of a Rapid Molecular Drug-Susceptibility Test for Tuberculosis. New England Journal of Medicine, 2017, 377, 1043-1054.	27.0	129
56	NOS2-deficient mice with hypoxic necrotizing lung lesions predict outcomes of tuberculosis chemotherapy in humans. Scientific Reports, 2017, 7, 8853.	3.3	22
57	Susceptibility of Mycobacterium tuberculosis Cytochrome bd Oxidase Mutants to Compounds Targeting the Terminal Respiratory Oxidase, Cytochrome c. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	49
58	Linking High-Throughput Screens to Identify MoAs and Novel Inhibitors of Mycobacterium tuberculosis Dihydrofolate Reductase. ACS Chemical Biology, 2017, 12, 2448-2456.	3.4	24
59	Novel Antitubercular 6-Dialkylaminopyrimidine Carboxamides from Phenotypic Whole-Cell High Throughput Screening of a SoftFocus Library: Structureâ€“Activity Relationship and Target Identification Studies. Journal of Medicinal Chemistry, 2017, 60, 10118-10134.	6.4	22
60	The bacillary and macrophage response to hypoxia in tuberculosis and the consequences for T cell antigen recognition. Microbes and Infection, 2017, 19, 177-192.	1.9	66
61	Detection of Isoniazid-, Fluoroquinolone-, Amikacin-, and Kanamycin-Resistant Tuberculosis in an Automated, Multiplexed 10-Color Assay Suitable for Point-of-Care Use. Journal of Clinical Microbiology, 2017, 55, 183-198.	3.9	47
62	Essential but Not Vulnerable: Indazole Sulfonamides Targeting Inosine Monophosphate Dehydrogenase as Potential Leads against Mycobacterium tuberculosis. ACS Infectious Diseases, 2017, 3, 18-33.	3.8	77
63	Interferon-gamma response to the treatment of active pulmonary and extra-pulmonary tuberculosis. International Journal of Tuberculosis and Lung Disease, 2017, 21, 1145-1149.	1.2	13
64	Using biomarkers to predict TB treatment duration (Predict TB): a prospective, randomized, noninferiority, treatment shortening clinical trial. Gates Open Research, 2017, 1, 9.	1.1	22
65	Bacterial Loads Measured by the Xpert MTB/RIF Assay as Markers of Culture Conversion and Bacteriological Cure in Pulmonary TB. PLoS ONE, 2016, 11, e0160062.	2.5	35
66	2-Aryl-8-aza-3-deazaadenosine analogues of 5â€²-O-[N-(salicyl)sulfamoyl]adenosine: Nucleoside antibiotics that block siderophore biosynthesis in Mycobacterium tuberculosis. Bioorganic and Medicinal Chemistry, 2016, 24, 3133-3143.	3.0	18
67	Inflammatory signaling in human tuberculosis granulomas is spatially organized. Nature Medicine, 2016, 22, 531-538.	30.7	273
68	Characterization of progressive HIV-associated tuberculosis using 2-deoxy-2-[18F]fluoro-D-glucose positron emission and computed tomography. Nature Medicine, 2016, 22, 1090-1093.	30.7	166
69	Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after tuberculosis cure. Nature Medicine, 2016, 22, 1094-1100.	30.7	247
70	Validation of CoaBC as a Bactericidal Target in the Coenzyme A Pathway of Mycobacterium tuberculosis. ACS Infectious Diseases, 2016, 2, 958-968.	3.8	62
71	Bioluminescent Reporters for Rapid Mechanism of Action Assessment in Tuberculosis Drug Discovery. Antimicrobial Agents and Chemotherapy, 2016, 60, 6748-6757.	3.2	38
72	SAR and identification of 2-(quinolin-4-yloxy)acetamides as Mycobacterium tuberculosis cytochrome bc₁ inhibitors. MedChemComm, 2016, 7, 2122-2127.	3.4	36

#	Article	IF	Citations
73	Pharmacological Inhibition of Host Heme Oxygenase-1 Suppresses Mycobacterium tuberculosis Infection In Vivo by a Mechanism Dependent on T Lymphocytes. MBio, 2016, 7, .	4.1	44
74	The impact of social conditions on patient adherence to pulmonary tuberculosis treatment. International Journal of Tuberculosis and Lung Disease, 2016, 20, 948-954.	1.2	19
75	Selective small molecule inhibitor of the Mycobacterium tuberculosis fumarate hydratase reveals an allosteric regulatory site. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 7503-7508.	7.1	36
76	Absolute Quantitative MALDI Imaging Mass Spectrometry: A Case of Rifampicin in Liver Tissues. Analytical Chemistry, 2016, 88, 2392-2398.	6.5	145
77	Mathematical Model of Oxygen Transport in Tuberculosis Granulomas. Annals of Biomedical Engineering, 2016, 44, 863-872.	2.5	29
78	Tuberculosis. Lancet, The, 2016, 387, 1211-1226.	13.7	480
79	Real-Time Investigation of Tuberculosis Transmission: Developing the Respiratory Aerosol Sampling Chamber (RASC). PLoS ONE, 2016, 11, e0146658.	2.5	40
80	Within patient microevolution of Mycobacterium tuberculosis correlates with heterogeneous responses to treatment. Scientific Reports, 2015, 5, 17507.	3.3	80
81	Major Global Killer Tamed by Hydrogen. ACS Central Science, 2015, 1, 286-288.	11.3	0
82	Dynamic exometabolome analysis reveals active metabolic pathways in nonâ€•replicating mycobacteria. Environmental Microbiology, 2015, 17, 4802-4815.	3.8	40
83	The Death of the â€œThree Msâ€• ACS Infectious Diseases, 2015, 1, 578-579.	3.8	1
84	Linezolid Trough Concentrations Correlate with Mitochondrial Toxicity-Related Adverse Events in the Treatment of Chronic Extensively Drug-Resistant Tuberculosis. EBioMedicine, 2015, 2, 1627-1633.	6.1	93
85	Molecular insights into the binding of coenzyme <scp>F₄₂₀</scp> to the conserved protein <scp>R</scp>v1155 from <scp>M</scp>ycobacterium tuberculosis. Protein Science, 2015, 24, 729-740.	7.6	16
86	Anti-vascular endothelial growth factor treatment normalizes tuberculosis granuloma vasculature and improves small molecule delivery. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 1827-1832.	7.1	167
87	Non-transpeptidase binding arylthioether Î²-lactams active against Mycobacterium tuberculosis and Moraxella catarrhalis. Bioorganic and Medicinal Chemistry, 2015, 23, 632-647.	3.0	6
88	Evolutionary history and global spread of the Mycobacterium tuberculosis Beijing lineage. Nature Genetics, 2015, 47, 242-249.	21.4	466
89	<scp>TB</scp> drug development: immunology at the table. Immunological Reviews, 2015, 264, 308-318.	6.0	43
90	Timing is everything for compassionate use of delamanid. Nature Medicine, 2015, 21, 211-211.	30.7	11

#	Article	IF	Citations
91	Linezolid for XDR-TB â€" Final Study Outcomes. New England Journal of Medicine, 2015, 373, 290-291.	27.0	69
92	Synthesis and Pharmacokinetic Evaluation of Siderophore Biosynthesis Inhibitors for Mycobacterium tuberculosis. Journal of Medicinal Chemistry, 2015, 58, 5459-5475.	6.4	46
93	Investigation and Conformational Analysis of Fluorinated Nucleoside Antibiotics Targeting Siderophore Biosynthesis. Journal of Organic Chemistry, 2015, 80, 4835-4850.	3.2	26
94	More than just bugs in spit. Science, 2015, 348, 633-634.	12.6	5
95	Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses. Immunological Reviews, 2015, 264, 288-307.	6.0	287
96	Host-Mediated Bioactivation of Pyrazinamide: Implications for Efficacy, Resistance, and Therapeutic Alternatives. ACS Infectious Diseases, 2015, 1, 203-214.	3.8	71
97	Aminopyrazolo[1,5-a]pyrimidines as potential inhibitors of Mycobacterium tuberculosis: Structure activity relationships and ADME characterization. Bioorganic and Medicinal Chemistry, 2015, 23, 7240-7250.	3.0	41
98	The association between sterilizing activity and drug distribution into tuberculosis lesions. Nature Medicine, 2015, 21, 1223-1227.	30.7	387
99	A Sterilizing Tuberculosis Treatment Regimen Is Associated with Faster Clearance of Bacteria in Cavitary Lesions in Marmosets. Antimicrobial Agents and Chemotherapy, 2015, 59, 4181-4189.	3.2	59
100	Treatment of Tuberculosis. New England Journal of Medicine, 2015, 373, 2149-2160.	27.0	290
101	Genotypic Susceptibility Testing of Mycobacterium tuberculosis Isolates for Amikacin and Kanamycin Resistance by Use of a Rapid Sloppy Molecular Beacon-Based Assay Identifies More Cases of Low-Level Drug Resistance than Phenotypic Lowenstein-Jensen Testing. Journal of Clinical Microbiology, 2015, 53, 43-51.	3.9	32
102	Comparative Evaluation of Sloppy Molecular Beacon and Dual-Labeled Probe Melting Temperature Assays to Identify Mutations in Mycobacterium tuberculosis Resulting in Rifampin, Fluoroquinolone and Aminoglycoside Resistance. PLoS ONE, 2015, 10, e0126257.	2.5	12
103	Pharmacokinetics-Pharmacodynamics Analysis of Bicyclic 4-Nitroimidazole Analogs in a Murine Model of Tuberculosis. PLoS ONE, 2014, 9, e105222.	2.5	23
104	Sensititre MYCOTB MIC Plate for Testing Mycobacterium tuberculosis Susceptibility to First- and Second-Line Drugs. Antimicrobial Agents and Chemotherapy, 2014, 58, 11-18.	3.2	86
105	PET/CT imaging reveals a therapeutic response to oxazolidinones in macaques and humans with tuberculosis. Science Translational Medicine, 2014, 6, 265ra167.	12.4	116
106	PET/CT imaging correlates with treatment outcome in patients with multidrug-resistant tuberculosis. Science Translational Medicine, 2014, 6, 265ra166.	12.4	126
107	Fitness costs of rifampicin resistance in <scp>M</scp>ycobacterium tuberculosis are amplified under conditions of nutrient starvation and compensated by mutation in the Î²â€² subunit of <scp>RNA</scp> polymerase. Molecular Microbiology, 2014, 91, 1106-1119.	2.5	85
108	Drug discovery goes au naturel. Nature, 2014, 506, 436-437.	27.8	9

#	Article	IF	Citations
109	The Three Mycobacterium tuberculosis Antigen 85 Isoforms Have Unique Substrates and Activities Determined by Non-active Site Regions. Journal of Biological Chemistry, 2014, 289, 25041-25053.	3.4	52
110	The ongoing challenge of latent tuberculosis. Philosophical Transactions of the Royal Society B: Biological Sciences, 2014, 369, 20130437.	4.0	250
111	Respiratory Flexibility in Response to Inhibition of Cytochrome c Oxidase in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2014, 58, 6962-6965.	3.2	116
112	Extensive Drug Resistance Acquired During Treatment of Multidrug-Resistant Tuberculosis. Clinical Infectious Diseases, 2014, 59, 1049-1063.	5.8	129
113	Predictors of pulmonary tuberculosis treatment outcomes in South Korea: a prospective cohort study, 2005-2012. BMC Infectious Diseases, 2014, 14, 360.	2.9	48
114	Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature, 2014, 511, 99-103.	27.8	650
115	Detection of stealthy small amphiphilic biomarkers. Journal of Microbiological Methods, 2014, 103, 112-117.	1.6	16
116	Some Nigerian anti-tuberculosis ethnomedicines: A preliminary efficacy assessment. Journal of Ethnopharmacology, 2014, 155, 524-532.	4.1	22
117	A medicinal chemistsâ€™ guide to the unique difficulties of lead optimization for tuberculosis. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 4741-4750.	2.2	93
118	A genetic strategy to identify targets for the development of drugs that prevent bacterial persistence. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 19095-19100.	7.1	167
119	Microenvironments in Tuberculous Granulomas Are Delineated by Distinct Populations of Macrophage Subsets and Expression of Nitric Oxide Synthase and Arginase Isoforms. Journal of Immunology, 2013, 191, 773-784.	0.8	292
120	Utility of the REBA MTB-rifaÂ® assay for rapid detection of rifampicin resistant Mycobacterium Tuberculosis. BMC Infectious Diseases, 2013, 13, 478.	2.9	9
121	Structureâ€“activity relationships of 2-aminothiazoles effective against Mycobacterium tuberculosis. Bioorganic and Medicinal Chemistry, 2013, 21, 6385-6397.	3.0	66
122	Efficacy and Safety of Metronidazole for Pulmonary Multidrug-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy, 2013, 57, 3903-3909.	3.2	67
123	Association of lipoarabinomannan with high density lipoprotein in blood: Implications for diagnostics. Tuberculosis, 2013, 93, 301-307.	1.9	46
124	Para -Aminosalicylic Acid Acts as an Alternative Substrate of Folate Metabolism in Mycobacterium tuberculosis. Science, 2013, 339, 88-91.	12.6	178
125	Chasing Koch's chimera. Lancet Infectious Diseases, The, 2013, 13, 289-291.	9.1	0
126	Non-Nucleoside Inhibitors of BasE, an Adenylating Enzyme in the Siderophore Biosynthetic Pathway of the Opportunistic Pathogen Acinetobacter baumannii. Journal of Medicinal Chemistry, 2013, 56, 2385-2405.	6.4	48

#	Article	IF	Citations
127	A novel <scp>F₄₂₀</scp>â€dependent antiâ€oxidant mechanism protects <scp>M</scp>ycobacterium tuberculosis against oxidative stress and bactericidal agents. Molecular Microbiology, 2013, 87, 744-755.	2.5	99
128	Structureâ€“activity relationships of antitubercular salicylanilides consistent with disruption of the proton gradient via proton shuttling. Bioorganic and Medicinal Chemistry, 2013, 21, 114-126.	3.0	53
129	Functional Role of Methylation of G518 of the 16S rRNA 530 Loop by GidB in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2013, 57, 6311-6318.	3.2	42
130	Exploring Alternative Biomaterials for Diagnosis of Pulmonary Tuberculosis in HIV-Negative Patients by Use of the GeneXpert MTB/RIF Assay. Journal of Clinical Microbiology, 2013, 51, 4161-4166.	3.9	42
131	Radiologic Responses in Cynomolgus Macaques for Assessing Tuberculosis Chemotherapy Regimens. Antimicrobial Agents and Chemotherapy, 2013, 57, 4237-4244.	3.2	156
132	Partial Complementation of Sinorhizobium meliloti bacA Mutant Phenotypes by the Mycobacterium tuberculosis BacA Protein. Journal of Bacteriology, 2013, 195, 389-398.	2.2	24
133	Differential Virulence and Disease Progression following Mycobacterium tuberculosis Complex Infection of the Common Marmoset (Callithrix jacchus). Infection and Immunity, 2013, 81, 2909-2919.	2.2	107
134	Identification of New Drug Targets and Resistance Mechanisms in Mycobacterium tuberculosis. PLoS ONE, 2013, 8, e75245.	2.5	223
135	Impact of Diabetes and Smoking on Mortality in Tuberculosis. PLoS ONE, 2013, 8, e58044.	2.5	71
136	Comment on: Identification of antimicrobial activity among FDA-approved drugs for combating Mycobacterium abscessus and Mycobacterium chelonae. Journal of Antimicrobial Chemotherapy, 2012, 67, 252-253.	3.0	7
137	Frequency of adverse reactions to first- and second-line anti-tuberculosis chemotherapy in a Korean cohort. International Journal of Tuberculosis and Lung Disease, 2012, 16, 961-966.	1.2	48
138	Pharmacokinetic Evaluation of the Penetration of Antituberculosis Agents in Rabbit Pulmonary Lesions. Antimicrobial Agents and Chemotherapy, 2012, 56, 446-457.	3.2	154
139	A Convergent Synthesis of Chiral Diaminopimelic Acid Derived Substrates for Mycobacterial l,d-Transpeptidases. Synthesis, 2012, 44, 3043-3048.	2.3	2
140	Linezolid for Treatment of Chronic Extensively Drug-Resistant Tuberculosis. New England Journal of Medicine, 2012, 367, 1508-1518.	27.0	496
141	Rapid, High-Throughput Detection of Rifampin Resistance and Heteroresistance in Mycobacterium tuberculosis by Use of Sloppy Molecular Beacon Melting Temperature Coding. Journal of Clinical Microbiology, 2012, 50, 2194-2202.	3.9	38
142	Rhabdomyolysis in a Patient Treated With Linezolid for Extensively Drug-Resistant Tuberculosis. Clinical Infectious Diseases, 2012, 54, 1624-1627.	5.8	21
143	Infection Dynamics and Response to Chemotherapy in a Rabbit Model of Tuberculosis using [¹⁸ F]2-Fluoro-Deoxy- <scp>d</scp> -Glucose Positron Emission Tomography and Computed Tomography. Antimicrobial Agents and Chemotherapy, 2012, 56, 4391-4402.	3.2	89
144	Dynamic Population Changes in Mycobacterium tuberculosis During Acquisition and Fixation of Drug Resistance in Patients. Journal of Infectious Diseases, 2012, 206, 1724-1733.	4.0	169

#	Article	IF	Citations
145	Meropenem inhibits <scp>D</scp>,<scp>D</scp>â€carboxypeptidase activity in <scp>M</scp>ycobacterium tuberculosis. Molecular Microbiology, 2012, 86, 367-381.	2.5	128
146	Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet, The, 2012, 380, 1406-1417.	13.7	193
147	Pathway-Selective Sensitization of Mycobacterium tuberculosis for Target-Based Whole-Cell Screening. Chemistry and Biology, 2012, 19, 844-854.	6.0	123
148	Detection and treatment of subclinical tuberculosis. Tuberculosis, 2012, 92, 447-452.	1.9	33
149	Meropenem-Clavulanic Acid Shows Activity against Mycobacterium tuberculosis In Vivo. Antimicrobial Agents and Chemotherapy, 2012, 56, 3384-3387.	3.2	89
150	SQ109 Targets MmpL3, a Membrane Transporter of Trehalose Monomycolate Involved in Mycolic Acid Donation to the Cell Wall Core of Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2012, 56, 1797-1809.	3.2	437
151	Metronidazole prevents reactivation of latent Mycobacterium tuberculosis infection in macaques. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 14188-14193.	7.1	109
152	Lipidomic discovery of deoxysiderophores reveals a revised mycobactin biosynthesis pathway in Mycobacterium tuberculosis. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 1257-1262.	7.1	61
153	A High-Throughput Screen To Identify Inhibitors of ATP Homeostasis in Non-replicating Mycobacterium tuberculosis. ACS Chemical Biology, 2012, 7, 1190-1197.	3.4	123
154	Rapid detection of Mycobacterium tuberculosis biomarkers in a sandwich immunoassay format using a waveguide-based optical biosensor. Tuberculosis, 2012, 92, 407-416.	1.9	78
155	Development of a Selective Activity-Based Probe for Adenylating Enzymes: Profiling MbtA Involved in Siderophore Biosynthesis from Mycobacterium tuberculosis. ACS Chemical Biology, 2012, 7, 1653-1658.	3.4	54
156	Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action. Future Microbiology, 2012, 7, 823-837.	2.0	248
157	Substrate specificity of the deazaflavinâ€dependent nitroreductase from Mycobacteriumâ€ftuberculosis responsible for the bioreductive activation of bicyclic nitroimidazoles. FEBS Journal, 2012, 279, 113-125.	4.7	70
158	Understanding latent tuberculosis: the key to improved diagnostic and novel treatment strategies. Drug Discovery Today, 2012, 17, 514-521.	6.4	87
159	Structure of Ddn, the Deazaflavin-Dependent Nitroreductase from Mycobacterium tuberculosis Involved in Bioreductive Activation of PA-824. Structure, 2012, 20, 101-112.	3.3	80
160	Mycolic acids as diagnostic markers for tuberculosis case detection in humans and drug efficacy in mice. EMBO Molecular Medicine, 2012, 4, 27-37.	6.9	61
161	Mechanism-based Inactivation by Aromatization of the Transaminase BioA Involved in Biotin Biosynthesis in Mycobaterium tuberculosis. Journal of the American Chemical Society, 2011, 133, 18194-18201.	13.7	34
162	High-Sensitivity MALDI-MRM-MS Imaging of Moxifloxacin Distribution in Tuberculosis-Infected Rabbit Lungs and Granulomatous Lesions. Analytical Chemistry, 2011, 83, 2112-2118.	6.5	235

#	Article	IF	Citations
163	The Medicinal Chemistry of Tuberculosis Chemotherapy. Topics in Medicinal Chemistry, 2011, , 47-124.	0.8	17
164	ESI-MS Assay of M. tuberculosis Cell Wall Antigen 85 Enzymes Permits Substrate Profiling and Design of a Mechanism-Based Inhibitor. Journal of the American Chemical Society, 2011, 133, 13232-13235.	13.7	32
165	Structureâ€“Activity Relationships of Antitubercular Nitroimidazoles. 3. Exploration of the Linker and Lipophilic Tail of ((S)-2-Nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-yl)-(4-trifluoromethoxybenzyl)amine (6-Amino PA-824).. Journal of Medicinal Chemistry, 2011, 54, 5639-5659.	6.4	38
166	Pyrazinamide Inhibits Trans-Translation in Mycobacterium tuberculosis. Science, 2011, 333, 1630-1632.	12.6	475
167	Rv2607 from Mycobacterium tuberculosis Is a Pyridoxine 5â€²-Phosphate Oxidase with Unusual Substrate Specificity. PLoS ONE, 2011, 6, e27643.	2.5	14
168	Lessons from Seven Decades of Antituberculosis Drug Discovery. Current Topics in Medicinal Chemistry, 2011, 11, 1216-1225.	2.1	29
169	Uptake of unnatural trehalose analogs as a reporter for Mycobacterium tuberculosis. Nature Chemical Biology, 2011, 7, 228-235.	8.0	202
170	C4-Alkylthiols with activity against Moraxella catarrhalis and Mycobacterium tuberculosis. Bioorganic and Medicinal Chemistry, 2011, 19, 6842-6852.	3.0	14
171	Bisubstrate Adenylation Inhibitors of Biotin Protein Ligase from Mycobacterium tuberculosis. Chemistry and Biology, 2011, 18, 1432-1441.	6.0	83
172	A Comparative Lipidomics Platform for Chemotaxonomic Analysis of Mycobacterium tuberculosis. Chemistry and Biology, 2011, 18, 1537-1549.	6.0	188
173	Reagent Precoated Targets for Rapid In-Tissue Derivatization of the Anti-Tuberculosis Drug Isoniazid Followed by MALDI Imaging Mass Spectrometry. Journal of the American Society for Mass Spectrometry, 2011, 22, 1409-1419.	2.8	65
174	The effect of 5-substitution on the electrochemical behavior and antitubercular activity of PA-824. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 812-817.	2.2	16
175	Rapid Detection of Fluoroquinolone-Resistant and Heteroresistant Mycobacterium tuberculosis by Use of Sloppy Molecular Beacons and Dual Melting-Temperature Codes in a Real-Time PCR Assay. Journal of Clinical Microbiology, 2011, 49, 932-940.	3.9	48
176	Improved rapid molecular diagnosis of multidrug-resistant tuberculosis using a new reverse hybridization assay, REBA MTB-MDR. Journal of Medical Microbiology, 2011, 60, 1447-1454.	1.8	25
177	Mutations in gidB Confer Low-Level Streptomycin Resistance in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2011, 55, 2515-2522.	3.2	130
178	Evaluating the Sensitivity of Mycobacterium tuberculosis to Biotin Deprivation Using Regulated Gene Expression. PLoS Pathogens, 2011, 7, e1002264.	4.7	127
179	Fumarate Reductase Activity Maintains an Energized Membrane in Anaerobic Mycobacterium tuberculosis. PLoS Pathogens, 2011, 7, e1002287.	4.7	221
180	Design of a nucleoside inhibitor of biotin protein ligase from Mycobacterium tuberculosis. , 2011, , .		0

#	Article	IF	Citations
181	Lessons from Seven Decades of Antituberculosis Drug Discovery. Current Topics in Medicinal Chemistry, 2011, 999, 1-10.	2.1	0
182	Synthesis of labeled meropenem for the analysis of M. tuberculosis transpeptidases. Tetrahedron Letters, 2010, 51, 197-200.	1.4	8
183	The chemical biology of new drugs in the development for tuberculosis. Current Opinion in Chemical Biology, 2010, 14, 456-466.	6.1	55
184	Spectrum of latent tuberculosis â€" existing tests cannot resolve the underlying phenotypes: author's reply. Nature Reviews Microbiology, 2010, 8, 242-242.	28.6	15
185	Mutations in Extensively Drugâ€ResistantMycobacterium tuberculosisThat Do Not Code for Known Drugâ€Resistance Mechanisms. Journal of Infectious Diseases, 2010, 201, 881-888.	4.0	22
186	Neutrophils Are the Predominant Infected Phagocytic Cells in the Airways of Patients With Active Pulmonary TB. Chest, 2010, 137, 122-128.	0.8	444
187	The Three RelE Homologs of Mycobacterium tuberculosis Have Individual, Drug-Specific Effects on Bacterial Antibiotic Tolerance. Journal of Bacteriology, 2010, 192, 1279-1291.	2.2	125
188	Association of Antigen-Stimulated Release of Tumor Necrosis Factor-Alpha in Whole Blood with Response to Chemotherapy in Patients with Pulmonary Multidrug-Resistant Tuberculosis. Respiration, 2010, 80, 275-284.	2.6	23
189	Genetic Diversity of Mycobacterium tuberculosis Isolates from a Tertiary Care Tuberculosis Hospital in South Korea. Journal of Clinical Microbiology, 2010, 48, 387-394.	3.9	73
190	Mycolic Acid/Cyclopropane Fatty Acid/Fatty Acid Biosynthesis and Health Relations. , 2010, , 65-145.		5
191	Clinical Pharmacology and Lesion Penetrating Properties of Second- and Third-Line Antituberculous Agents Used in the Management of Multidrug-Resistant (MDR) and Extensively-Drug Resistant (XDR) Tuberculosis. Current Clinical Pharmacology, 2010, 5, 96-114.	0.6	39
192	Tuberculosis: What We Donâ€™t Know Can, and Does, Hurt Us. Science, 2010, 328, 852-856.	12.6	430
193	Polymorphisms Associated with Resistance and Cross-Resistance to Aminoglycosides and Capreomycin in Mycobacterium tuberculosis Isolates from South Korean Patients with Drug-Resistant Tuberculosis. Journal of Clinical Microbiology, 2010, 48, 402-411.	3.9	83
194	Age and the epidemiology and pathogenesis of tuberculosis. Lancet, The, 2010, 375, 1852-1854.	13.7	132
195	Metaplastic ossification in the cartilage of the bronchus of a patient with chronic multi-drug resistant tuberculosis: a case report. Journal of Medical Case Reports, 2010, 4, 156.	0.8	8
196	Expansion of the mycobacterial â€œPUPylomeâ€• Molecular BioSystems, 2010, 6, 376-385.	2.9	83
197	Proteasomal Protein Degradation in Mycobacteria Is Dependent upon a Prokaryotic Ubiquitin-like Protein. Journal of Biological Chemistry, 2009, 284, 3069-3075.	3.4	126
198	Clifton E. Barry, III: TB's strategic opponent. Journal of Experimental Medicine, 2009, 206, 494-495.	8.5	1

#	Article	IF	Citations
199	BacA, an ABC Transporter Involved in Maintenance of Chronic Murine Infections withMycobacterium tuberculosis. Journal of Bacteriology, 2009, 191, 477-485.	2.2	76
200	The mechanism of action of PA-824. Communicative and Integrative Biology, 2009, 2, 215-218.	1.4	278
201	Unorthodox Approach to the Development of a New Antituberculosis Therapy. New England Journal of Medicine, 2009, 360, 2466-2467.	27.0	25
202	The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nature Reviews Microbiology, 2009, 7, 845-855.	28.6	1,179
203	New Tactics Against Tuberculosis. Scientific American, 2009, 300, 62-69.	1.0	5
204	Defining the Mode of Action of Tetramic Acid Antibacterials Derived from Pseudomonas aeruginosa Quorum Sensing Signals. Journal of the American Chemical Society, 2009, 131, 14473-14479.	13.7	80
205	Structureâ^'Activity Relationships of Antitubercular Nitroimidazoles. 2. Determinants of Aerobic Activity and Quantitative Structureâ^'Activity Relationships. Journal of Medicinal Chemistry, 2009, 52, 1329-1344.	6.4	82
206	Meropenem-Clavulanate Is Effective Against Extensively Drug-Resistant Mycobacterium tuberculosis. Science, 2009, 323, 1215-1218.	12.6	477
207	Structureâ^'Activity Relationships of Antitubercular Nitroimidazoles. 1. Structural Features Associated with Aerobic and Anaerobic Activities of 4- and 5-Nitroimidazoles. Journal of Medicinal Chemistry, 2009, 52, 1317-1328.	6.4	101
208	Synthesis and antitubercular activity of 7-(R)- and 7-(S)-methyl-2-nitro-6-(S)-(4-(trifluoromethoxy)benzyloxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazines, analogues of PA-824. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 2256-2262.	2.2	62
209	Inhibition of Siderophore Biosynthesis by 2-Triazole Substituted Analogues of 5â€²-O-[N-(Salicyl)sulfamoyl]adenosine: Antibacterial Nucleosides Effective against Mycobacterium tuberculosis. Journal of Medicinal Chemistry, 2008, 51, 7495-7507.	6.4	83
210	PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO Release. Science, 2008, 322, 1392-1395.	12.6	568
211	Confronting the scientific obstacles to global control of tuberculosis. Journal of Clinical Investigation, 2008, 118, 1255-1265.	8.2	266
212	Evaluation of the diagnostic utility of a whole-blood interferon-Î³ assay for determining the risk of exposure to Mycobacterium tuberculosis in Bacille Calmette-Guerin (BCG)-vaccinated individuals. Diagnostic Microbiology and Infectious Disease, 2008, 61, 181-186.	1.8	19
213	Inhibition of Siderophore Biosynthesis in Mycobacterium tuberculosis with Nucleoside Bisubstrate Analogues: Structureâ^'Activity Relationships of the Nucleobase Domain of 5â€²-O-[N-(Salicyl)sulfamoyl]adenosine. Journal of Medicinal Chemistry, 2008, 51, 5349-5370.	6.4	118
214	Tuberculous Granulomas Are Hypoxic in Guinea Pigs, Rabbits, and Nonhuman Primates. Infection and Immunity, 2008, 76, 2333-2340.	2.2	570
215	Biosynthesis and Recycling of Nicotinamide Cofactors in Mycobacterium tuberculosis. Journal of Biological Chemistry, 2008, 283, 19329-19341.	3.4	152
216	Extensively Drug-Resistant Tuberculosis in South Korea: Risk Factors and Treatment Outcomes among Patients at a Tertiary Referral Hospital. Clinical Infectious Diseases, 2008, 46, 42-49.	5.8	94

#	Article	IF	Citations
217	Expression, production and release of the Eis protein by Mycobacterium tuberculosis during infection of macrophages and its effect on cytokine secretion. Microbiology (United Kingdom), 2007, 153, 529-540.	1.8	51
218	Targeting the Formation of the Cell Wall Core of M. tuberculosis. Infectious Disorders - Drug Targets, 2007, 7, 182-202.	0.8	97
219	5â€˜-O-[(N-Acyl)sulfamoyl]adenosines as Antitubercular Agents that Inhibit MbtA:â€‰An Adenylation Enzyme Required for Siderophore Biosynthesis of the Mycobactins. Journal of Medicinal Chemistry, 2007, 50, 6080-6094.	6.4	85
220	The W-Beijing Lineage of Mycobacterium tuberculosis Overproduces Triglycerides and Has the DosR Dormancy Regulon Constitutively Upregulated. Journal of Bacteriology, 2007, 189, 2583-2589.	2.2	215
221	Design, Synthesis, and Biological Evaluation of Î²-Ketosulfonamide Adenylation Inhibitors as Potential Antitubercular Agents. Organic Letters, 2006, 8, 4707-4710.	4.6	65
222	Structureâ^'Activity Relationships at the 5-Position of Thiolactomycin:Â An Intact (5R)-Isoprene Unit Is Required for Activity against the Condensing Enzymes fromMycobacteriumtuberculosisandEscherichiacoli. Journal of Medicinal Chemistry, 2006, 49, 159-171.	6.4	79
223	Rationally Designed Nucleoside Antibiotics That Inhibit Siderophore Biosynthesis ofMycobacteriumtuberculosis. Journal of Medicinal Chemistry, 2006, 49, 31-34.	6.4	214
224	Is the mycobacterial cell wall a hopeless drug target for latent tuberculosis?. Drug Discovery Today Disease Mechanisms, 2006, 3, 237-245.	0.8	23
225	Antitubercular Nucleosides That Inhibit Siderophore Biosynthesis:Â SAR of the Glycosyl Domain. Journal of Medicinal Chemistry, 2006, 49, 7623-7635.	6.4	78
226	A genome-wide sequence-independent comparative analysis of insertionâ€“deletion polymorphisms in multiple Mycobacterium tuberculosis strains. Research in Microbiology, 2006, 157, 282-290.	2.1	6
227	Quantification of small molecule organic acids fromMycobacterium tuberculosis culture supernatant using ion exclusion liquid chromatography/mass spectrometry. Rapid Communications in Mass Spectrometry, 2006, 20, 3345-3350.	1.5	8
228	Next-generation therapeutics. Current Opinion in Chemical Biology, 2006, 10, 291-293.	6.1	2
229	Novel route to 5-position vinyl derivatives of thiolactomycin: olefination versus deformylation. Tetrahedron Letters, 2006, 47, 3447-3451.	1.4	12
230	Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 431-436.	7.1	325
231	Mycobacterium leprae Is Naturally Resistant to PA-824. Antimicrobial Agents and Chemotherapy, 2006, 50, 3350-3354.	3.2	42
232	Antimycobacterial natural products: synthesis and preliminary biological evaluation of the oxazole-containing alkaloid texaline. Tetrahedron Letters, 2005, 46, 7355-7357.	1.4	96
233	Getting the iron out. Nature Chemical Biology, 2005, 1, 127-128.	8.0	14
234	A low-carb diet for a high-octane pathogen. Nature Medicine, 2005, 11, 599-600.	30.7	18

#	Article	IF	Citations
235	Tuberculosis â€" metabolism and respiration in the absence of growth. Nature Reviews Microbiology, 2005, 3, 70-80.	28.6	403
236	Virulence of SelectedMycobacterium tuberculosisClinical Isolates in the Rabbit Model of Meningitis Is Dependent on Phenolic Glycolipid Produced by the Bacilli. Journal of Infectious Diseases, 2005, 192, 98-106.	4.0	228
237	Elemental Analysis ofMycobacterium avium-,Mycobacterium tuberculosis-, andMycobacterium smegmatis-Containing Phagosomes Indicates Pathogen-Induced Microenvironments within the Host Cellâ€™s Endosomal System. Journal of Immunology, 2005, 174, 1491-1500.	0.8	389
238	In Vivo Phenotypic Dominance in Mouse Mixed Infections withMycobacterium tuberculosisClinical Isolates. Journal of Infectious Diseases, 2005, 192, 600-606.	4.0	57
239	Contribution of the Mycobacterium tuberculosis MmpL Protein Family to Virulence and Drug Resistance. Infection and Immunity, 2005, 73, 3492-3501.	2.2	306
240	HypervirulentM. tuberculosisW/Beijing Strains Upregulate Type I IFNs and Increase Expression of Negative Regulators of the Jak-Stat Pathway. Journal of Interferon and Cytokine Research, 2005, 25, 694-701.	1.2	267
241	Differential Monocyte Activation Underlies Strain-Specific Mycobacterium tuberculosis Pathogenesis. Infection and Immunity, 2004, 72, 5511-5514.	2.2	200
242	The Role of MmpL8 in Sulfatide Biogenesis and Virulence of Mycobacterium tuberculosis. Journal of Biological Chemistry, 2004, 279, 21257-21265.	3.4	142
243	A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response. Nature, 2004, 431, 84-87.	27.8	673
244	Inhibition of Mycobacterium tuberculosis AhpD, an Element of the Peroxiredoxin Defense against Oxidative Stress. Antimicrobial Agents and Chemotherapy, 2004, 48, 2424-2430.	3.2	17
245	The Transcriptional Responses of Mycobacterium tuberculosis to Inhibitors of Metabolism. Journal of Biological Chemistry, 2004, 279, 40174-40184.	3.4	547
246	Tuberculosis â€“ strategies towards anti-infectives for a chronic disease. Drug Discovery Today: Therapeutic Strategies, 2004, 1, 491-496.	0.5	4
247	Prospects for new antitubercular drugs. Current Opinion in Microbiology, 2004, 7, 460-465.	5.1	122
248	Prospects for Clinical Introduction of Nitroimidazole Antibiotics for the Treatment of Tuberculosis. Current Pharmaceutical Design, 2004, 10, 3239-3262.	1.9	123
249	Synthesis and Spectroscopic Differentiation of 2- and 4-Alkoxythio-tetronic Acids. Heterocycles, 2004, 63, 519.	0.7	9
250	Top down characterization of secreted proteins from Mycobacterium tuberculosis by electron capture dissociation mass spectrometry. Journal of the American Society for Mass Spectrometry, 2003, 14, 253-261.	2.8	76
251	Combinatorial Lead Optimization of [1,2]-Diamines Based on Ethambutol as Potential Antituberculosis Preclinical Candidates. ACS Combinatorial Science, 2003, 5, 172-187.	3.3	205
252	Mycobacterium tuberculosisGrowth at theCavity Surface: a Microenvironment with FailedImmunity. Infection and Immunity, 2003, 71, 7099-7108.	2.2	306

#	Article	IF	Citations
253	DnaE2 Polymerase Contributes to In Vivo Survival and the Emergence of Drug Resistance in Mycobacterium tuberculosis. Cell, 2003, 113, 183-193.	28.9	383
254	Mycobacterium tuberculosisInhibits Maturation of Human Monocyteâ€Derived Dendritic Cells In Vitro. Journal of Infectious Diseases, 2003, 188, 257-266.	4.0	95
255	Unique Mechanism of Action of the Thiourea Drug Isoxyl on Mycobacterium tuberculosis. Journal of Biological Chemistry, 2003, 278, 53123-53130.	3.4	145
256	The role of RelMtb-mediated adaptation to stationary phase in long-term persistence of Mycobacterium tuberculosis in mice. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 10026-10031.	7.1	310
257	Hypoxic Response of Mycobacterium tuberculosis Studied by Metabolic Labeling and Proteome Analysis of Cellular and Extracellular Proteins. Journal of Bacteriology, 2002, 184, 3485-3491.	2.2	183
258	Effects of Pyrazinamide on Fatty Acid Synthesis by Whole Mycobacterial Cells and Purified Fatty Acid Synthase I. Journal of Bacteriology, 2002, 184, 2167-2172.	2.2	128
259	The role of KasA and KasB in the biosynthesis of meromycolic acids and isoniazid resistance in Mycobacterium tuberculosis. Tuberculosis, 2002, 82, 149-160.	1.9	93
260	Inactivation of theMycobacterium tuberculosis Nramporthologue (mntH) does not affect virulence in a mouse model of tuberculosis. FEMS Microbiology Letters, 2002, 207, 81-86.	1.8	33
261	Mycobacterium tuberculosis in the post-genomic age. Current Opinion in Microbiology, 2001, 4, 28-34.	5.1	47
262	â€˜Imagination is more important than knowledgeâ€™. Trends in Microbiology, 2001, 9, 192.	7.7	6
263	Interpreting cell wall 'virulence factors' of Mycobacterium tuberculosis. Trends in Microbiology, 2001, 9, 237-241.	7.7	100
264	Mycobacterium smegmatis: an absurd model for tuberculosis?. Trends in Microbiology, 2001, 9, 473-474.	7.7	23
265	The Specificity of Methyl Transferases Involved in trans Mycolic Acid Biosynthesis in Mycobacterium tuberculosis and Mycobacterium smegmatis. Bioorganic Chemistry, 2001, 29, 164-177.	4.1	16
266	Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-Â/Â. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 5752-5757.	7.1	544
267	Analysis of the Lipids of Mycobacterium tuberculosis. , 2001, 54, 229-245.		46
268	Isoniazid affects multiple components of the type II fatty acid synthase system of Mycobacterium tuberculosis. Molecular Microbiology, 2000, 38, 514-525.	2.5	134
269	The genetics and biochemistry of isoniazid resistance in Mycobacterium tuberculosis. Microbes and Infection, 2000, 2, 659-669.	1.9	171
270	A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature, 2000, 405, 962-966.	27.8	971

#	Article	IF	Citations
271	Use of genomics and combinatorial chemistry in the development of new antimycobacterial drugs. Biochemical Pharmacology, 2000, 59, 221-231.	4.4	124
272	The salicylate-derived mycobactin siderophores of Mycobacterium tuberculosis are essential for growth in macrophages. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 1252-1257.	7.1	500
273	Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 9677-9682.	7.1	314
274	A Point Mutation in the mma3 Gene Is Responsible for Impaired Methoxymycolic Acid Production in Mycobacterium bovis BCG Strains Obtained after 1927. Journal of Bacteriology, 2000, 182, 3394-3399.	2.2	95
275	Cell Wall Structure of a Mutant of Mycobacterium smegmatis Defective in the Biosynthesis of Mycolic Acids. Journal of Biological Chemistry, 2000, 275, 7224-7229.	3.4	57
276	DNA microarrays: translational tools for understanding the biology of Mycobacterium tuberculosis. Trends in Microbiology, 2000, 8, 209-210.	7.7	10
277	The Stringent Response of Mycobacterium tuberculosis Is Required for Long-Term Survival. Journal of Bacteriology, 2000, 182, 4889-4898.	2.2	306
278	The development of new chemotherapeutics for multidrug-resistant tuberculosis. Resurgent and Emerging Infectious Diseases, 2000, , 241-252.	0.2	0
279	AhpC, oxidative stress and drug resistance in Mycobacterium tuberculosis. BioFactors, 1999, 10, 211-217.	5.4	55
280	Mycobacterium tuberculosisCatalase and Peroxidase Activities and Resistance to Oxidative Killing in Human Monocytes In Vitro. Infection and Immunity, 1999, 67, 74-79.	2.2	223
281	Iron Acquisition and Metabolism by Mycobacteria. Journal of Bacteriology, 1999, 181, 4443-4451.	2.2	232
282	Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature, 1998, 393, 537-544.	27.8	7,357
283	Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature, 1998, 396, 190-190.	27.8	119
284	Mechanisms involved in the intrinsic isoniazid resistance ofMycobacterium avium. Molecular Microbiology, 1998, 27, 1223-1233.	2.5	76
285	The effect of oxygenated mycolic acid composition on cell wall function and macrophage growth inMycobacterium tuberculosis. Molecular Microbiology, 1998, 29, 1449-1458.	2.5	161
286	Mycolic acids: structure, biosynthesis and physiological functions. Progress in Lipid Research, 1998, 37, 143-179.	11.6	504
287	Inhibition of a Mycobacterium tuberculosis -Ketoacyl ACP Synthase by Isoniazid. Science, 1998, 280, 1607-1610.	12.6	398
288	Mechanisms of isoniazid resistance in Mycobacterium tuberculosis. Drug Resistance Updates, 1998, 1, 128-134.	14.4	25

#	Article	IF	Citations
289	The Biosynthesis of Mycolic Acids in Mycobacterium tuberculosis. Journal of Biological Chemistry, 1998, 273, 21282-21290.	3.4	61
290	The 16-kDa Î±-crystallin (Acr) protein ofMycobacterium tuberculosisis required for growth in macrophages. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 9578-9583.	7.1	300
291	MMAS-1, the Branch Point Between cis- and trans-Cyclopropane-containing Oxygenated Mycolates in Mycobacterium tuberculosis. Journal of Biological Chemistry, 1997, 272, 10041-10049.	3.4	85
292	New horizons in the treatment of tuberculosis. Biochemical Pharmacology, 1997, 54, 1165-1172.	4.4	62
293	Drug sensitivity and environmental adaptation of myocobacterial cell wall components. Trends in Microbiology, 1996, 4, 275-281.	7.7	97
294	Compensatory ahpC Gene Expression in Isoniazid-Resistant Mycobacterium tuberculosis. Science, 1996, 272, 1641-1643.	12.6	411
295	Stationary phase-associated protein expression in Mycobacterium tuberculosis: function of the mycobacterial alpha-crystallin homolog. Journal of Bacteriology, 1996, 178, 4484-4492.	2.2	309
296	A common mechanism for the biosynthesis of methoxy and cyclopropyl mycolic acids in Mycobacterium tuberculosis. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 12828-12833.	7.1	140
297	Mycolic Acid Structure Determines the Fluidity of the Mycobacterial Cell Wall. Journal of Biological Chemistry, 1996, 271, 29545-29551.	3.4	236
298	Biochemical and Genetic Data Suggest that InhA Is Not the Primary Target for Activated Isoniazid in Mycobacterium tuberculosis. Journal of Infectious Diseases, 1996, 174, 1085-1090.	4.0	115
299	Identification of a gene involved in the biosynthesis of cyclopropanated mycolic acids in Mycobacterium tuberculosis.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 6630-6634.	7.1	190
300	Disparate responses to oxidative stress in saprophytic and pathogenic mycobacteria.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 6625-6629.	7.1	193
301	The Biosynthesis of Cyclopropanated Mycolic Acids in Mycobacterium tuberculosis. Journal of Biological Chemistry, 1995, 270, 27292-27298.	3.4	162
302	Hc1-mediated effects on DNA structure: a potential regulator of chlamydial development. Molecular Microbiology, 1993, 9, 273-283.	2.5	74
303	Diversity in the Chlamydia trachomatis histone homologue Hc2. Gene, 1993, 132, 137-141.	2.2	39
304	Molecular cloning and expression of hctB encoding a strain-variant chlamydial histone-like protein with DNA-binding activity. Journal of Bacteriology, 1993, 175, 4274-4281.	2.2	76
305	Nucleoid Condensation in Escherichia coli That Express a Chlamydial Histone Homolog. Science, 1992, 256, 377-379.	12.6	119
306	Phenoxazinone synthase: mechanism for the formation of the phenoxazinone chromophore of actinomycin. Biochemistry, 1989, 28, 6323-6333.	2.5	168

#	Article	IF	Citations
307	Phenoxazinone synthase: enzymatic catalysis of an aminophenol oxidative cascade. Journal of the American Chemical Society, 1988, 110, 3333-3334.	13.7	104
308	Desacetyluvaricin from Uvaria accuminata, Configuration of Uvaricin at C-36. Journal of Natural Products, 1985, 48, 644-645.	3.0	63